{"entity":{"id":"tumor-bed-cellularity","kind":"term","name":"Tumour-bed cellularity","aka":["tumour bed cellularity","residual tumour bed cellularity"],"tldr":"Tumour-bed cellularity estimates cancer-occupied area within a defined treated breast bed. The in situ share uses a different denominator.","summary":"Label the region, numerator and denominator before interpreting cellularity. Overall cancer area and the in situ share of that cancer are separate RCB inputs, neither interchangeable with sequencing purity or a score by itself.","asOf":"2026-11-11","links":[{"label":"MD Anderson detailed RCB pathology methods","url":"https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/clinical-calculators/PLM_protocol_RCB_calculators_BRO.pdf"},{"label":"CAP invasive breast resection protocol 4.11.0.0, June 2026","url":"https://www.cap.org/wp-content/uploads/2026/06/Breast.Invasive.Res_4.11.0.0.REL_CAPCP.pdf?download=true"},{"label":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.","url":"https://pubmed.ncbi.nlm.nih.gov/17785706/"}],"tags":[],"related":["rcb","treatment-effect-in-pathology","pcr"],"cancers":["breast-cancer"],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["For RCB, overall cancer cellularity estimates the area occupied by invasive plus in situ cancer within a defined residual breast bed. The in situ percentage instead uses the cancer component as denominator. Microscopic review can revise bed boundaries and should represent sparse as well as dense regions; selecting only a dense focus changes the measurement.","Invasive bed fraction equals overall cancer fraction multiplied by one minus the in situ fraction of cancer. In a fictional 100-unit bed with 20 units of cancer, 25% in situ means 5 bed units in situ and 15 invasive. The invasive share is 75% of cancer but only 15% of the whole bed. These idealised area units teach denominators, not counting instructions or the precision of a clinical estimate.","Area occupied by cancer, the proportion of counted cells that are malignant and the fraction of sequenced DNA contributed by cancer have different denominators. A selected assay block may also differ from the whole residual bed. Do not enter an area-cellularity estimate as sequencing purity or describe 25% of cancer as 25% of the bed.","Retain the named bed, specimen, treatment setting, mapping and representative sections, overall area percentage and in situ share separately. Incomplete sampling, a misdefined bed and heterogeneous distribution can bias the estimate; staining or sampling consumes finite tissue. There is no universal low/high cellularity cutoff that alone selects treatment.","Cellularity alone supplies neither nodal burden, final margins, distant status, pCR nor an RCB score. CAP's residual-invasive RCB span excludes DCIS, while the MD Anderson protocol estimates invasive plus in situ area in a microscopically revised cancer bed. Neither is interchangeable with the largest contiguous ypT focus. CAP advises against RCB score/class after neoadjuvant endocrine therapy, although individual residual measurements may still be useful.","The MD Anderson protocol estimates overall cellularity and in situ percentage to the nearest 10%, with additional 1% and 5% choices for low values. The 25% in situ example above is fictional denominator arithmetic outside those listed estimation increments. Its arithmetic remains 20 × 0.25 = 5 in situ and 20 - 5 = 15 invasive bed units. A separate protocol-aligned 20% in situ illustration would give 4 in situ and 16 invasive units. Neither should be confused with the RCB example using 50% in situ.","Two fictional treated breast beds can have the same dimensions while one contains sparse residual carcinoma and the other dense residual carcinoma. The footprint alone cannot distinguish their viable cancer area. Read overall cancer area and the in situ share of that cancer with their different denominators, then keep regional nodes and final margins separate. A DCIS-permitting breast-and-node pCR definition can be met when DCIS remains at an involved final edge but no residual invasive breast or nodal cancer is found. Add an involved regional node and that combined endpoint is no longer met, even with a negative blood assay; this does not by itself establish distant spread."],"category":"Clinic basics"},"route":"/terms/tumor-bed-cellularity/","neighbours":{"term":[{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/"},{"id":"treatment-effect-in-pathology","kind":"term","name":"Treatment effect in breast pathology","route":"/terms/treatment-effect-in-pathology/"},{"id":"tumor-stroma-ratio","kind":"term","name":"Tumour-stroma ratio","route":"/terms/tumor-stroma-ratio/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}]}}